Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.78
INCY's Cash to Debt is ranked higher than
56% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. INCY: 0.78 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.78

Equity to Asset -0.11
INCY's Equity to Asset is ranked higher than
52% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: -0.11 )
INCY' s 10-Year Equity to Asset Range
Min: -1.83   Max: 0.84
Current: -0.11

-1.83
0.84
F-Score: 3
Z-Score: 7.51
M-Score: -0.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.97
INCY's Operating margin (%) is ranked higher than
83% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. INCY: 0.97 )
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53   Max: 9.05
Current: 0.97

-4064.53
9.05
Net-margin (%) -11.23
INCY's Net-margin (%) is ranked higher than
81% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. INCY: -11.23 )
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45   Max: 7.67
Current: -11.23

-4565.45
7.67
ROA (%) -8.72
INCY's ROA (%) is ranked higher than
82% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. INCY: -8.72 )
INCY' s 10-Year ROA (%) Range
Min: -70.43   Max: 5.19
Current: -8.72

-70.43
5.19
ROC (Joel Greenblatt) (%) 11.24
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. INCY: 11.24 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38   Max: 47.33
Current: 11.24

-4727.38
47.33
Revenue Growth (3Y)(%) 19.50
INCY's Revenue Growth (3Y)(%) is ranked higher than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. INCY: 19.50 )
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4   Max: 194.1
Current: 19.5

-61.4
194.1
EPS Growth (3Y)(%) 29.10
INCY's EPS Growth (3Y)(%) is ranked higher than
58% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. INCY: 29.10 )
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1   Max: 64.9
Current: 29.1

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INCY Guru Trades in Q1 2014

George Soros 23,200 sh (New)
Vanguard Health Care Fund 4,901,968 sh (+9.97%)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc Sold Out
Mariko Gordon 112,623 sh (-12.67%)
Steven Cohen 42,149 sh (-60.73%)
» More
Q2 2014

INCY Guru Trades in Q2 2014

Louis Moore Bacon 100,000 sh (New)
Ken Fisher 12,225 sh (New)
Vanguard Health Care Fund 9,591,143 sh (+95.66%)
George Soros Sold Out
Mariko Gordon 23,728 sh (-78.93%)
» More
Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
Q4 2014

INCY Guru Trades in Q4 2014

Jim Simons 244,800 sh (+150.01%)
Ken Fisher 14,870 sh (+97.08%)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Mariko Gordon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2014-12-31 Sold Out 0.05%$45.6 - $78.89 $ 85.8531%0
Ken Fisher 2014-12-31 Add 97.08%$45.6 - $78.89 $ 85.8532%14870
Ken Fisher 2014-09-30 Reduce -38.28%$45.35 - $55.78 $ 85.8572%7545
Vanguard Health Care Fund 2014-06-30 Add 95.66%0.68%$43.1 - $56.39 $ 85.8568%9591143
Mariko Gordon 2014-06-30 Reduce -78.93%0.19%$43.1 - $56.39 $ 85.8568%23728
George Soros 2014-06-30 Sold Out 0.01%$43.1 - $56.39 $ 85.8568%0
Ken Fisher 2014-06-30 New Buy$43.1 - $56.39 $ 85.8568%12225
George Soros 2014-03-31 New Buy0.01%$49.94 - $68.83 $ 85.8539%23200
Mariko Gordon 2013-12-31 Reduce -20.5%0.06%$34.71 - $51.34 $ 85.8598%128959
Vanguard Health Care Fund 2013-06-30 Add 21.52%0.05%$19.07 - $24.49 $ 85.85293%3807443
Vanguard Health Care Fund 2013-03-31 New Buy0.29%$16.61 - $24.95 $ 85.85320%3133100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp

Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Aramark, Incyte Corp Ltd. and Facebook Inc. Read more...
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Aramark, Incyte Corp Ltd, Emeritus Corp, and Huntsman Corp. Read more...

Ratios

vs
industry
vs
history
Forward P/E 60.61
INCY's Forward P/E is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 60.61 )
N/A
P/S 30.88
INCY's P/S is ranked higher than
74% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. INCY: 30.88 )
INCY' s 10-Year P/S Range
Min: 7.19   Max: 209.75
Current: 30.88

7.19
209.75
EV-to-EBIT 3169.75
INCY's EV-to-EBIT is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 3169.75 )
INCY' s 10-Year EV-to-EBIT Range
Min: -672   Max: 3568
Current: 3169.75

-672
3568
Current Ratio 5.32
INCY's Current Ratio is ranked higher than
67% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. INCY: 5.32 )
INCY' s 10-Year Current Ratio Range
Min: 1.51   Max: 21.14
Current: 5.32

1.51
21.14
Quick Ratio 5.31
INCY's Quick Ratio is ranked higher than
69% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. INCY: 5.31 )
INCY' s 10-Year Quick Ratio Range
Min: 1.51   Max: 21.14
Current: 5.31

1.51
21.14
Days Inventory 175.18
INCY's Days Inventory is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 175.18 )
INCY' s 10-Year Days Inventory Range
Min: 198.14   Max: 323.15
Current: 175.18

198.14
323.15
Days Sales Outstanding 82.55
INCY's Days Sales Outstanding is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. INCY: 82.55 )
INCY' s 10-Year Days Sales Outstanding Range
Min: 12.25   Max: 6447.52
Current: 82.55

12.25
6447.52

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.37
INCY's Price/Median PS Value is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. INCY: 1.37 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 7.5
Current: 1.37

0.1
7.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp Ltd was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company's drug discovery and development activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its product candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries. The Company's trademaks include Incyte and JAKAFI. The Company's operations are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of the employees.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 


More From Other Websites
Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera –... Feb 26 2015
Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera –... Feb 26 2015
Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015
Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3... Feb 23 2015
Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3... Feb 23 2015
INCYTE CORP Financials Feb 21 2015
Insider Selling Remains Choppy as Stock Market Grinds Higher Feb 21 2015
10-K for Incyte Corp. Feb 19 2015
INCYTE CORP Files SEC form 10-K, Annual Report Feb 17 2015
Incyte to Present at Upcoming Investor Conferences Feb 17 2015
Incyte to Present at Upcoming Investor Conferences Feb 17 2015
Incyte Corporation (INCY): New Analyst Report from Zacks Equity Research - Zacks Equity Research... Feb 16 2015
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog Feb 13 2015
Incyte reports 4Q loss Feb 12 2015
Incyte reports 4Q loss Feb 12 2015
Should You Sell Incyte (INCY) Before Earnings? - Tale of the Tape Feb 12 2015
Incyte Corp Earnings Call scheduled for 8:30 am ET today Feb 12 2015
INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 12 2015
Q4 2014 Incyte Corp Earnings Release - 07:00 am ET Feb 12 2015
Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance;... Feb 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK